BCMU
VRTX icon

BlueCrest Capital Management (UK)’s Vertex Pharmaceuticals VRTX Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,741
Closed -$544K – 695
2014
Q2 		$544K Buy
+5,741
New +$403K 0.02% 443

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BlueCrest Capital Management (UK)'s VRTX Position: Q3 2014 in Review

BlueCrest Capital Management (UK) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2014, closing a stake of 5,741 shares — an estimated $544K sold.

BlueCrest Capital Management (UK) first reported a position in VRTX in Q2 2014 and held it in 1 quarter. The position peaked at $544K in Q2 2014. 430 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

  • BlueCrest Capital Management (UK) reported no remaining Vertex Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 5,741 Vertex Pharmaceuticals shares in Q3 2014, an estimated $544K.
  • BlueCrest Capital Management (UK) first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Vertex Pharmaceuticals position peaked at $544K in Q2 2014.
  • 430 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q3 2014, filed 13 Nov 2014.